Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.

@article{Byrd1997ExtramedullaryLA,
  title={Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.},
  author={John C. Byrd and Raymond B. Weiss and Diane C. Arthur and David Lawrence and Maria R. Baer and Frederick R. Davey and E S Trikha and Andrew J. Carroll and Ramana Tantravahi and Mazin Qumsiyeh and Shivanand R. Patil and Joseph O. Moore and Robert J. Mayer and Charles A Schiffer and Clara D. Bloomfield},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1997},
  volume={15 2},
  pages={466-75}
}
PURPOSE To examine the prognostic significance of extramedullary leukemia (EML) at presentation in patients with t(8;21)(q22;q22) karyotype. PATIENTS AND METHODS Consecutive patients with t(8;21) treated on Cancer and Leukemia Group B de novo acute myeloid leukemia (AML) treatment studies were examined for the presence of EML (granulocytic sarcoma, subcutaneous nodules, leukemia cutis, or meningeal leukemia) at initial presentation. Clinical features and outcome of t(8;21) patients with and… CONTINUE READING